Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

American Heart Journal
Adam B GreenbaumW Douglas Weaver

Abstract

Platelet-initiated acute thrombosis and coronary embolization are fundamental in the pathophysiology of complications during percutaneous coronary intervention (PCI). Cangrelor (formerly AR-C69931MX) is a novel, rapidly acting, intravenous, specific antagonist of platelet aggregation via binding to the adenosine diphosphate (ADP) P2Y12 receptor subtype. The primary aims of this study were to assess the initial safety and pharmacodynamics of cangrelor in patients undergoing PCI. In part 1, patients undergoing PCI were randomized to an 18- to 24-hour of either placebo, 1-, 2-, or 4-microg/kg per minute cangrelor in addition to aspirin and heparin beginning before PCI. In part 2, patients were randomized to receive either cangrelor (4 microg/kg per minute) or abciximab before PCI. The primary end point was the composite incidence of major and minor bleeding through 7 days. Secondary end points included the occurrence of major adverse coronary events (death, MI, and unplanned repeat coronary intervention) through 30 days plus ex vivo platelet aggregation and bleeding times. Two hundred patients (3 dosage groups and placebo) were studied in part 1, and 199 additional patients were then randomized in the second part, comparing 1 dose...Continue Reading

References

Dec 1, 1996·Journal of the American College of Cardiology·H Le BretonE J Topol
Jan 16, 2004·The New England Journal of Medicine·Adnan KastratiUNKNOWN Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators

❮ Previous
Next ❯

Citations

Mar 11, 2008·Cardiovascular Drugs and Therapy·Sharmalar Rajendran, Yuliy Y Chirkov
Nov 18, 2006·Journal of Thrombosis and Thrombolysis·Gouri ShankerDavid C Sane
Jan 22, 2010·Journal of Thrombosis and Thrombolysis·S Michael GharacholouJohn H Alexander
May 14, 2010·Journal of Thrombosis and Thrombolysis·Matthew A Cavender, Sunil V Rao
Feb 24, 2010·Internal and Emergency Medicine·Marco Cattaneo, Gian Marco Podda
Mar 24, 2007·Current Treatment Options in Cardiovascular Medicine·Seung-Jung Park, Seung-Whan Lee
Oct 12, 2012·International Journal of Hematology·Fatemeh Moheimani, Denise E Jackson
May 26, 2009·JACC. Cardiovascular Interventions·Dean J Kereiakes, Paul A Gurbel
Feb 23, 2007·International Journal of Clinical Practice·V L SerebruanyD Atar
Apr 28, 2009·International Journal of Clinical Practice·A SiddiqueG Y H Lip
Apr 12, 2011·Thrombosis and Haemostasis·Robert F Storey
May 20, 2009·Future Cardiology·Jan SmidHarald F Langer
Apr 26, 2014·Future Cardiology·Julie H Oestreich, Paul P Dobesh
Sep 24, 2013·Journal of Thrombosis and Thrombolysis·Partha SardarFerdinand Visco
Jun 1, 2014·Current Cardiology Reports·Marcello MarinoSergio Leonardi
Feb 1, 2014·Medicina clínica·Antonio Tello-MontoliuMariano Valdés
Jul 10, 2008·Current Cardiology Reports·Colin M Barker, Matthew J Price
Oct 10, 2009·Expert Review of Cardiovascular Therapy·José Luis FerreiroDominick J Angiolillo
Jul 31, 2010·Expert Review of Cardiovascular Therapy·Masafumi UenoDominick J Angiolillo
Apr 30, 2013·Expert Review of Cardiovascular Therapy·David C YangDmitriy N Feldman
Nov 30, 2012·Expert Review of Cardiovascular Therapy·Rachel F PowerThomas J Kiernan
Dec 4, 2009·Expert Review of Cardiovascular Therapy·Laurent BonelloFranck Paganelli
Feb 1, 2014·Expert Opinion on Pharmacotherapy·Joseph A Walsh, Matthew J Price
Jul 31, 2013·Expert Review of Cardiovascular Therapy·Michele D Voeltz, Steven V Manoukian
Dec 19, 2015·Expert Opinion on Drug Safety·Francesco FranchiDominick J Angiolillo
Jul 16, 2013·Expert Opinion on Emerging Drugs·Yuichi J Shimada, Robert P Giugliano
Aug 15, 2009·Expert Opinion on Investigational Drugs·Italo PortoFilippo Crea
Apr 12, 2007·Expert Opinion on Pharmacotherapy·Andrew J Lucking, David E Newby
Mar 3, 2015·Expert Opinion on Drug Metabolism & Toxicology·Eleonora Tamborini PermunianAlessandro Squizzato
Jul 17, 2009·Expert Opinion on Investigational Drugs·Nicholas B Norgard
Jan 8, 2014·Current Medical Research and Opinion·Jacek KubicaPaul Alfred Gurbel
May 8, 2009·Current Medical Research and Opinion·Michael J Cowley, Louis Kuritzky
Jan 24, 2016·Pharmacology & Therapeutics·Arman Qamar, Deepak L Bhatt
Jun 16, 2010·Pharmacology & Therapeutics·Dimitris TousoulisChristodoulos Stefanadis
Feb 16, 2010·Current Problems in Cardiology·Rahul SakhujaDeepak L Bhatt
Nov 7, 2009·European Journal of Internal Medicine·Massimo Franchini, Pier Mannuccio Mannucci
Jul 22, 2009·Annals of Vascular Surgery·William M StoneSamuel R Money
May 9, 2008·Revista española de cardiología·Lina Badimon, Gemma Vilahur
Jul 6, 2007·Heart, Lung & Circulation·Ernesto OqueliRonald Dick
Nov 18, 2006·Thrombosis Research·Paul A Gurbel, Udaya S Tantry
Jul 28, 2009·Journal of Thrombosis and Haemostasis : JTH·M Cattaneo
May 28, 2009·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Marc Cohen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.